At first glance life science venture capitalists must have it easy, given a pile of cash to invest in a huge $1.8T market healthcare market and smart scientists generating new biomedical insights, surely a return on capital is guaranteed? However as the data from Cambridge Associates and the landmark Kauffman report “WE HAVE MET THE ENEMY… AND HE IS US” show, returns to LPs have been rare over the last decade.
A recent development at Biolauncher has been to work alongside venture firms to help shape their new fund raising strategy based on analysis of global investment trends, industry deal making and future industry needs. We have also been commissioned by prospective Limited Partners to gather the evidence to support their commitments to new funds.
Through our networks we are connected to a rich network of organisations funding and investing in the life science sector. We track the development of new fund models that are striving to find better ways of funding innovation critical to the improvement of human health and well being.